Biotechnology & Medical Research

Page 1

Leaf Resources Ltd raises $1,707,000 in placement

Thursday, 30 Oct 2014 06:43pm EDT

Leaf Resources Ltd:Says that it has received acceptances for placement of 11,380,000 ordinary shares at $0.15, which will raise $1,707,000.Funds raised will be used to provide extra working capital for commercialisation of the company's GlycellTM process.

Chimerix Inc prices public offering of common stock

Thursday, 30 Oct 2014 06:37pm EDT

Chimerix Inc:Prices of underwritten public offering of 3,650,000 shares of its common stock at price to public of $29 per share.Gross proceeds to Chimerix from this offering, before deducting underwriting discounts and commissions and other offering expenses payable by Chimerix, are expected to be about $105.9 million.Expects expected to close on or about Nov. 5.Anticipates using net proceeds from offering to fund its research and development efforts and for general corporate purposes, including working capital.Morgan Stanley & Co. LLC and J.P. Morgan Securities LLC are acting as joint book-running managers for offering.Cowen and Company, LLC, Piper Jaffray & Co. and Stifel, Nicolaus & Company, Incorporated are acting as co-lead managers for offering.Cantor Fitzgerald & Co. and Brean Capital, LLC are acting as co-managers for offering.Says that it has granted underwriters 30-day option to purchase up to aggregate of 547,500 additional shares of common stock.

Genexine, completes private placement of common shares

Thursday, 30 Oct 2014 02:55am EDT

Genexine, Inc:Says completed private placement of 1,094,110 shares of common stock as of Oct. 30, and raised proceeds of 50,000,827,000 won from the issuance.

Starpharma raises $3.5M following $18M Placement

Thursday, 30 Oct 2014 02:16am EDT

Starpharma Holdings Ltd:Announces that it has raised a total of about $21.5 million following the closing of its share purchase plan (SPP) on Oct. 29.Says the company raised about $3.5 million from existing eligible shareholders through the SPP.Says the additional funds will allow Starpharma to confidently advance programs across all areas of the business including commercialisation activities for VivaGel for Symptomatic Relief of BV and pivotal Phase 3 clinical trials for VivaGelĀ® prevention of recurrence of BV.Says advancing the drug delivery and agrochemical programs; and strengthen the balance sheet for the various commercialisation discussions already underway.

Chimerix Inc announces commencement of public offering of common stock

Wednesday, 29 Oct 2014 04:55pm EDT

Chimerix Inc:Intends to offer and sell, subject to market and other conditions, about $105,000,000 of its common stock in an underwritten public offering.In connection with this offering, Chimerix expects to grant the underwriters a 30-day option to purchase up to about $15,750,000 of additional shares of its common stock.Morgan Stanley & Co. LLC and J.P. Morgan Securities LLC are acting as joint book-running managers for the offering, and Cowen and Company, LLC, Piper Jaffray & Co. and Stifel, Nicolaus & Company, Incorporated are acting as co-lead managers for the offering.Offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the size or terms of the offering.Chimerix anticipates using the net proceeds from the offering to fund its research and development efforts and for general corporate purposes, including working capital.

DiaMedica Inc announces pricing of previously announced public offering

Wednesday, 29 Oct 2014 04:34pm EDT

DiaMedica Inc:Announced public offering of Units of DiaMedica with a syndicate of agents led by Mackie Research Capital Corporation as sole book-runner of the Offering, and including Jordan Capital Markets Inc.Offering will be priced at $0.25 per Unit for minimum gross proceeds of about $3,000,000 and maximum gross proceeds of about $6,000,000 representing 12,000,000 and 24,000,000 Units respectively.Each Unit shall consist of one common share ("Common Shares") and one common share purchase warrant.Each Warrant will entitle the holder thereof to acquire one Common Share of the Company at a price per share of $0.32 for a period of 36 months following the issuance thereof.Intends to use the net proceeds from the Offering principally to satisfy all remaining contractual obligations of the Phase II study of DM199 in patients with type 2 diabetes and for general and administrative purposes as described more fully in the Prospectus.

Vanda Pharmaceuticals Inc prices public offering of common stock

Wednesday, 29 Oct 2014 09:00am EDT

Vanda Pharmaceuticals Inc:Says the sale of 5,000,000 shares of its common stock in an underwritten public offering at a price to the public of $11.60 per share.The net offering proceeds to Vanda from the sale of the shares are expected to be about $54.0 million, after deducting underwriting discounts and commissions and other estimated offering expenses, but excluding any exercise of the underwriters' option to purchase additional shares of common stock.It anticipates using the net proceeds from this offering for sales and marketing expenditures in connection with the commercialization of HETLIOZ in the U.S. for the treatment of Non-24-Hour Sleep-Wake Disorder, research and development activities and other general corporate purposes.The offering is expected to close on or about Nov. 3.In addition, Vanda has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of common stock on the same terms and conditions.Jefferies LLC and Piper Jaffray & Co. are acting as the joint book-running managers and JMP Securities LLC and Canaccord Genuity Inc. are acting as co-managers for the offering.

Regulus Therapeutics Inc announces pricing of public offering of common stock

Tuesday, 28 Oct 2014 08:10pm EDT

Regulus Therapeutics Inc:Prices underwritten public offering of 5,294,118 shares of its common stock at a price to public of $17.00 per share.4,411,765 shares are being sold by Regulus and 882,353 shares are being sold by an existing stockholder of Regulus, Isis Pharmaceuticals, Inc.Regulus and Isis have granted underwriters a 30-day option to purchase up to additional 794,117 shares of common stock in aggregate.Expects offering to close on or about Nov. 3.Net proceeds to Regulus from offering, excluding any exercise by underwriters of their 30-day option to purchase additional shares, are expected to be about $69.8 million after deducting underwriting discounts and commissions and other estimated offering expenses payable by Regulus.Says that it will not receive any proceeds from sale of the shares of common stock by Isis.Anticipates using net proceeds from offering to fund preclinical and clinical development of its clinical candidates, RG-101 and RG*012, and its other initial microRNA development candidates, for identification and validation of additional microRNA targets.And for capital expenditures, working capital and general corporate purposes.Deutsche Bank Securities and BMO Capital Markets are acting as joint book-running managers for offering.Needham & Company, Wedbush PacGrow Life Sciences and FBR are acting as co-managers.

AtheroNova Inc prices public offering of common stock and warrants

Tuesday, 28 Oct 2014 05:58pm EDT

AtheroNova Inc:Prices an underwritten public offering of 4,000,000 shares of its common stock and warrants to purchase up to an aggregate of 5,000,000 shares of its common stock, with each share of common stock being sold together with 1.25 warrants to purchase one share of common stock.Securities are offered at a price to the public of $0.75 per share of common stock and $0.01 per warrant.Warrants will have an exercise price of $4.00 per share, and are exercisable immediately and will expire five years from the date of issuance.Gross proceeds from this offering to AtheroNova are expected to be $3,050,000.AtheroNova has granted the underwriters a 45-day option to purchase up to an additional 600,000 shares of its common stock and/or warrants to purchase up to an aggregate of 750,000 shares of its common stock.Offering is expected to close on or about Oct. 31.Intends to use the net proceeds, as well as its other existing capital resources, for general corporate purposes, including working capital, operating expenses and capital expenditures.Aegis Capital Corp. is acting as the sole book-running manager for the offering.Merriman Capital is acting as co-manager for the offering.

Vanda Pharmaceuticals Inc proposes public offering of common stock

Tuesday, 28 Oct 2014 04:01pm EDT

Vanda Pharmaceuticals Inc:Intends to offer and sell shares of its common stock in an underwritten public offering.Offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.Expects to grant the underwriters a 30-day option to purchase up to an additional 15 pct of the shares of common stock offered in the public offering.Jefferies LLC and Piper Jaffray & Co. are acting as the joint book-running managers for the offering.

Markets

  • Sectors
  • U.S.
  • Europe
  • Asia

Sector Summary

Analyst Research

Report Title Price
Provider: Thomson Reuters StreetEvents
$75.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.